Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $103.70 | Total: $518.50 |
| 1 | 10 | $87.84 | Total: $878.40 |
| 1 | 25 | $74.42 | Total: $1,860.50 |
| 1 | 50 | $63.44 | Total: $3,172.00 |
| 1 | 100 | $54.90 | Total: $5,490.00 |
Overview
Nanterinone (UK 61260), an orally available partial phosphodiesterase inhibitor, is a novel positive inotropic and balanced vasodilator compound.Nanterinone, when administered orally, results in significant improvements in acute haemodynamics, which may depend on pre-existing left ventricular filling pressures.Nanterinone is a novel positive inotropic and balanced vasodilator that has demonstrated acute hemodynamic effects in patients with mild to moderate heart failure.
Chemical Properties
| Molecular Formula | C15H15N3O |
| Molecular Weight | 253.3 |
| CAS Numbers | 102791-47-9 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CC=1N(C=C(C)N1)C=2C=C3C(=C(C)C2)NC(=O)C=C3 |
Storage and Handling
0C Short Term, -20C Long Term
References
Remme WJ, et al. Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure. Cardiovasc Drugs Ther. 1996 May ; 10[2] 137-144.